Alternative splicing of RNA is a mechanism that is used to regulate gene expression during cell growth and differentiation. The role of this mechanism has been examined in regulating the replicative capacity of HIV. Many of the splice donor and acceptor motifs in the infectious clone of HIV, pNL4-3, have been mutated, yielding viruses that fail to produce the full complement of spliced mRNAs. Analyses of the biological and biochemical properties of these viruses indicate that they exhibit patterns of protein expression and altered growth kinetics despite the apparent redundancy of splicing signals. A semi-quantitative PCR assay has been developed that determines the relative proportions of alternatively spliced HIV mRNA species during infection. This assay is being used in conjunction with mutagenesis studies to examine HIV mRNA expression in different cell types and correlate the expression of alternatively spliced mRNAs with the biological and biochemical properties of HIV generated in these cells. A sensitive system to monitor the cell-to-cell transmission of HIV-1 has been developed which utilizes chronically infected H9 donor cells. Studies with this system have shown that virus induced cell-cell fusion occurs within 15 to 30 minutes of co-culture as monitored by electron microscopy, sCD4 competition and dye-diffusion analysis. This system has also been used to evaluate HIV-1 infection of activated and resting human PBLs. Activated unfractionated PBLs synthesize viral DNA 4 to 6 hrs. following incubation with infected H9 cells and produce progeny virions by 22 hrs. post infection. Viral DNA is also produced in resting unstimulated PBLs (to approximately 40% the level observed in activated cells) but no detectable progeny virions are produced. Linear as well as circular forms of viral DNA are synthesized in resting PBLs indicating that the nuclear transport of reverse transcripts is not inhibited. Studies are underway to ascertain whether the integration step of the virus life cycle is blocked in unstimulated PBLs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000190-14
Application #
3790682
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
1992
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Lafont, Bernard A P; McGraw, Christopher M; Stukes, Sabriya A et al. (2007) The locus encoding an oligomorphic family of MHC-A alleles (Mane-A*06/Mamu-A*05) is present at high frequency in several macaque species. Immunogenetics 59:211-23
Igarashi, Tatsuhiko; Donau, Olivia K; Imamichi, Hiromi et al. (2007) Although macrophage-tropic simian/human immunodeficiency viruses can exhibit a range of pathogenic phenotypes, a majority of isolates induce no clinical disease in immunocompetent macaques. J Virol 81:10669-79
Mao, Hanwen; Lafont, Bernard A P; Igarashi, Tatsuhiko et al. (2005) CD8+ and CD20+ lymphocytes cooperate to control acute simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys: modulation by major histocompatibility complex genotype. J Virol 79:14887-98
Mattapallil, Joseph J; Douek, Daniel C; Hill, Brenna et al. (2005) Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434:1093-7
Nishimura, Yoshiaki; Brown, Charles R; Mattapallil, Joseph J et al. (2005) Resting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques. Proc Natl Acad Sci U S A 102:8000-5
Lafont, Bernard A P; Buckler-White, Alicia; Plishka, Ron et al. (2004) Pig-tailed macaques (Macaca nemestrina) possess six MHC-E families that are conserved among macaque species: implication for their binding to natural killer receptor variants. Immunogenetics 56:142-54
Willey, Ronald L; Byrum, Russ; Piatak, Michael et al. (2003) Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles. J Virol 77:1163-74
Lifson, Jeffrey D; Martin, Malcolm A (2002) One step forwards, one step back. Nature 415:272-3
Nishimura, Yoshiaki; Igarashi, Tatsuhiko; Haigwood, Nancy et al. (2002) Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 76:2123-30
Cho, M W; Kim, Y B; Lee, M K et al. (2001) Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. J Virol 75:2224-34

Showing the most recent 10 out of 14 publications